Phase 1 Trial of Ovarian Cancer Therapy Mirvetuximab Supports Phase 3 Study

Phase 1 Trial of Ovarian Cancer Therapy Mirvetuximab Supports Phase 3 Study
Results from a Phase 1 clinical trial of mirvetuximab soravtansine (IMGN853) as a treatment for  chemotherapy-resistant ovarian cancer and other malignancies have propelled the therapy into a Phase 3 trial. Researchers used the Phase 1 findings to determine a suitable dose for further trials, according to the treatment’s developer, ImmunoGen. The study, “Phase 1 Dose-Escalation Study of

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *